The 32nd Annual
Cancer Progress Conference

May 4-6, 2021

❝ Inspiring Cancer Progress through engaged stakeholder dialogue ❞



It is time for everyone to save the date for Cancer Progress! With the success of our 1st virtual event, it is our pleasure to announce our 32nd Annual and 2nd virtual.

With the success of our first virtual conference, we are looking to expand to three days and are considering adding a partnering component.

We are incredibly grateful for the donations we received during Cancer Progress 2020. With your help we raised close to $20,000 and donated to:




Keynote Speaker Day One

Engineering the Future: Next Gen Platforms in Oncology

Daniel S. Chen, MD, PhD

Tuesday, May 4, 2021 | 9:15 – 10:00 am EDT

Chief Medical Officer


Keynote Speaker Day Two

Off-the-shelf CAR-engineered NK cells for the treatment of cancer

Katy Rezvani, MD, PhD

Wednesday, May 5, 2021 | 9:15 – 10:00 am EDT

Principal Investigator, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine

Cancer Progress Conference Panels Include...

Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors

Multifunctional Soluble Biologics: Binders, Binders Everywhere

Tumor Agnostic Development

Accelerated Development Paths

Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?

Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)

Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)

Cell Therapy in Solid Tumors: Freedom of the Open Road

Validating New Platforms: Clinical Pain, Commercial Gain

Counterpoint to Engineered Platforms: Less is More


Investing in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My!

Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML

Let’s Make a Deal in Oncology: What’s Behind the Doors & Who Has the Keys? Value Panel

Battle of the Modalities- The sequel

Cancer Progress 2020 Panel Summaries

As a preview of the good things to expect from Cancer Progress 2021, we’re excited to roll out summaries of select sessions from Cancer Progress 2020, starting with a summary of the panel “Paradigm Shifting Platforms II – Non-IO: Targeting Better, Targeting the Intractable” that highlights the key opportunities and challenges of non-IO targeted approaches and how even they cannot be thought of independently from IO.


Paradigm Shifting Platforms I –IO: Taking IO to the Next Level

Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable

Oncology Modalities Facing Off: Room for Many or One to Rule them All


Good array of opinions and technologies. Well curated

Andrew Allen, MD, PhD, President & CEO

Gritstone Oncology

As I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!

Michael G. King, Jr., Entrepreneur in Residence

Fortress Biotech Inc.

When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts

Mark Simon, Managing Director


“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa


“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company